Inmune Bio, Inc. has announced a pivotal securities purchase agreement aimed at raising $4.5 million through a registered direct offering. This move is significant for the company as it seeks to bolster its financial foundation in a competitive market.

The agreement, made on October 27, 2026, involves the sale of 3,000,000 shares of common stock at an offering price of $1.50 per share. Additionally, the company will issue unregistered warrants allowing the investor to purchase up to 3,000,000 shares of common stock at an exercise price of $1.65 per share. The offering is expected to close on October 29, 2026, subject to customary closing conditions.

Background

Inmune Bio, Inc. is classified under the SIC code 2836, which covers Biological Products, (No Diagnostic Substances). The company trades on the Nasdaq under the ticker symbol INMB. It is incorporated in Nevada and operates primarily from Boca Raton, Florida.

What the Filing Says

The recent SEC filing details that Inmune Bio will receive aggregate gross proceeds of $4.5 million from the offering, before deducting placement agent fees and offering expenses. The shares were sold under the company’s shelf registration statement, declared effective by the SEC on August 7, 2024.

Impact

This capital infusion may significantly impact Inmune Bio's operational capabilities and research initiatives. The funds could be utilized for advancing its product pipeline, which is crucial in the highly competitive biological products sector. The agreement also includes provisions for the resale of the common warrant shares, potentially enhancing liquidity for the investor.

What's Next

The offering is set to close soon, with the company also planning to file a registration statement for the resale of common warrant shares. This step is expected to occur within 30 days following the closing date of the offering.